Overview

Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose

Status:
Not yet recruiting

Trial end date:
2022-04-22

Target enrollment:

Participant gender:

Summary

Pilot study evaluating the feasibility and clinical utility of extended-release injectable buprenorphine (XR-BUP) for the treatment of opioid use disorder (OUD) among individuals at high-risk for overdose (OD).

Phase:

Phase 4

Details

Lead Sponsor:

M. Eugenia Socias

Collaborator:

Indivior Inc.

Treatments:

Buprenorphine